EUVIMEDEUVIMED entdecken
Fallbericht

First Use of Maribavir in Poland to Treat Refractory CMV Disease in a Patient After Kidney Transplantation

Anna Pawłowska, Norbert Kwella, Justyna Zbrzeźniak-Suszczewicz, Monika Knysak, Tomasz Stompór

Transplantation Proceedings · 2025

DOI: 10.1016/j.transproceed.2025.02.008 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Anna Pawłowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hypertension, and Internal Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland. Hauptthemen laut MEDLINE: Kidney Transplantation, Cytomegalovirus Infections, Antiviral Agents, Ribonucleosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs). In this article, we presented the case of a 39-year-old patient with end-stage renal disease after kidney transplantation with refractory CMV infection, who was successfully treated with maribavir for the first time in Poland. The use of maribavir resulted in a significant reduction of CMV viremia in ganciclovir/valganciclovir-resistant CMV infection and resolution of CMV disease symptoms in the absence of drug-related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCytomegalovirus InfectionsAntiviral AgentsRibonucleosidesBenzimidazolesHumansAdultPolandMaleKidney Failure, ChronicTreatment OutcomeDrug Resistance, ViralDichlororibofuranosylbenzimidazole

Substanzen

Antiviral AgentsRibonucleosidesmaribavirBenzimidazolesDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • Department of Nephrology, Hypertension, and Internal Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Department of Nephrology, Hypertension, and Internal Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland. Electronic address: stompin@mp.pl.

Zitieren

APA

Pawłowska, A., Kwella, N., Zbrzeźniak-Suszczewicz, J., Knysak, M., & Stompór, T. (2025). First Use of Maribavir in Poland to Treat Refractory CMV Disease in a Patient After Kidney Transplantation. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.02.008

Vancouver

Pawłowska A, Kwella N, Zbrzeźniak-Suszczewicz J, Knysak M, Stompór T. First Use of Maribavir in Poland to Treat Refractory CMV Disease in a Patient After Kidney Transplantation. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.02.008

BibTeX
@article{Pawowska2025,
  author = {Pawłowska, Anna and Kwella, Norbert and Zbrzeźniak-Suszczewicz, Justyna and Knysak, Monika and Stompór, Tomasz},
  title = {First Use of Maribavir in Poland to Treat Refractory CMV Disease in a Patient After Kidney Transplantation},
  journal = {Transplantation Proceedings},
  year = {2025},
  doi = {10.1016/j.transproceed.2025.02.008}
}
Kostenlos starten →